NAVB Navidea Biopharmaceuticals, Inc. gains 29% Jan 21, 2020

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company offers Lymphoseek, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its neurological development programs include NAV4694, an Fluorine-18 labeled positron emission tomography imaging agent, which is used as an aid the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment; and NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.http://www.priceseries.com/trade/NAVB-Navidea-Biopharmaceuticals-Inc-stock-gains-29-percent-a-Trade-Record-by-priceSeries-2019122420200121.html